Skip to main content
. Author manuscript; available in PMC: 2017 Sep 15.
Published in final edited form as: Clin Cancer Res. 2016 May 25;22(18):4585–4593. doi: 10.1158/1078-0432.CCR-15-3101

Figure 2.

Figure 2

PD-L1 expression levels in paired, pre- and post-TKI biopsies among EGFR-mutant patients along with representative PD-L1 immunohistochemical images. A majority of EGFR-mutant patients (72%) exhibited consistent PD-L1 staining across both specimens, but 16 (28%) patients demonstrated variable staining across biopsies.